⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
GTBP News
GT Biopharma Inc. Common Stock
Platform Technologies Drive $211B Surge in Precision Cancer Treatment
prnewswire.com
GTBP
ERAS
FHTX
OABI
RXRX
THE REALITY CHECK: 5 Assets Delivering Proof in a Speculative Market
globenewswire.com
DGNX
GTBP
Blood Cancer Therapeutics Reach Critical Commercial and Clinical Inflection Points
prnewswire.com
GTBP
GERN
KURA
SLS
TCRX
GT Biopharma, Inc. (NASDAQ:GTBP) Offers Near-Term Catalyst Opportunity with Advancing Phase 1 Trials
accessnewswire.com
GTBP
GT Biopharma Reports Third Quarter 2025 Financial Results and Provides Corporate Update
globenewswire.com
GTBP
GT Biopharma Provides Enrollment Update on GTB-3650 Phase 1 Trial in Patients with Relapsed or Refractory (r/r) CD33 Expressing Hematologic Malignancies
globenewswire.com
GTBP
Natural Killer Cell Therapies Lead $254B Immunotherapy Market Transformation
prnewswire.com
GTBP
EVAX
RNXT
EDAP
XNCR
GTBP
EVAX
RNXT
EDAP
XNCR
Precision Oncology Approaches Drive $312B Market Transformation
prnewswire.com
GTBP
NRIX
GRAL
CCCC
PFE
GTBP
NRIX
GRAL
CCCC
PFE
Next-Generation Targeted Therapies Reshape Precision Oncology Landscape
prnewswire.com
GTBP
IDYA
ZYME
NVS
REGN
GTBP
IDYA
ZYME
NVS
REGN
Cellular Immunotherapy Breakthroughs Fuel $370 Billion Market Surge
prnewswire.com
GTBP
GDTC
PSTV
IOVA
IMAB
GTBP
GDTC
PSTV
IOVA
IMAB